Express Mail Label:

PTO/SB/08b (08-03)
Approved for use through 06/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a visid OMB control number.

	Substitute for form 1449B/PTO				Complete if Known			
					Application Number	10/629,466		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				SURE	Filing Date			
				CANT	First Named Inventor	Anandan Palani		
					Art Unit	Art Unit 1625		
		(Use es many sheets	as necessary)		Examiner Name	Celia C. Chang		
	Sheet	1	of	1	Aftomey Docket Number	IN01481KB		

	NON PATENT LITERATURE DOCUMENTS					
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
/CC/	AA	MOLLA et al., "Human Serum Attenuates the Activity of Protease Inhibitors toward Wild-Type and Mutant Human Immunodeficiency Virus", Virology (1998), p. 255-262, vol. 250.				
/CC/	AB	PETERSON et al., "Influence of Protein Bindingen Therapeutic Efficacy of Cefoperazone", Antimicrobial Agents and Chemotherapy (Apr. 1989), p. 566-568, Vol. 33, No. 4.				
/CC/	AC	PETERSON et al., "Effect of Protein Binding on Simulated Intravascular and Extravascular Kinetics of Cefotaxime in an In Vitro Model", Antimicrobial Agents and Chemotherapy (Jan. 1984), p. 58-61, Vol. 25, No. 1				

m+200+++100++100+100+100+100+100+100+100+						
·			ļ			
16 to 7 to 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	************					
			 			
			ļ			

-				
	Examiner Signature	/Celia Chang/	Date Considered	06/12/2007

^{*}EXAMINER: trittal if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of his form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commence, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.